Literature DB >> 23861904

Exosomal signaling during hypoxia mediates microvascular endothelial cell migration and vasculogenesis.

Carlos Salomon1, Jennifer Ryan, Luis Sobrevia, Miharu Kobayashi, Keith Ashman, Murray Mitchell, Gregory E Rice.   

Abstract

Vasculogenesis and angiogenesis are critical processes in fetal circulation and placental vasculature development. Placental mesenchymal stem cells (pMSC) are known to release paracrine factors (some of which are contained within exosomes) that promote angiogenesis and cell migration. The aims of this study were: to determine the effects of oxygen tension on the release of exosomes from pMSC; and to establish the effects of pMSC-derived exosomes on the migration and angiogenic tube formation of placental microvascular endothelial cells (hPMEC). pMSC were isolated from placental villi (8-12 weeks of gestation, n = 6) and cultured under an atmosphere of 1%, 3% or 8% O2. Cell-conditioned media were collected and exosomes (exo-pMSC) isolated by differential and buoyant density centrifugation. The dose effect (5-20 µg exosomal protein/ml) of pMSC-derived exosomes on hPMEC migration and tube formation were established using a real-time, live-cell imaging system (Incucyte™). The exosome pellet was resuspended in PBS and protein content was established by mass spectrometry (MS). Protein function and canonical pathways were identified using the PANTHER program and Ingenuity Pathway Analysis, respectively. Exo-pMSC were identified, by electron microscopy, as spherical vesicles, with a typical cup-shape and diameters around of 100 nm and positive for exosome markers: CD63, CD9 and CD81. Under hypoxic conditions (1% and 3% O2) exo-pMSC released increased by 3.3 and 6.7 folds, respectively, when compared to the controls (8% O2; p<0.01). Exo-pMSC increased hPMEC migration by 1.6 fold compared to the control (p<0.05) and increased hPMEC tube formation by 7.2 fold (p<0.05). MS analysis identified 390 different proteins involved in cytoskeleton organization, development, immunomodulatory, and cell-to-cell communication. The data obtained support the hypothesis that pMSC-derived exosomes may contribute to placental vascular adaptation to low oxygen tension under both physiological and pathological conditions.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23861904      PMCID: PMC3704530          DOI: 10.1371/journal.pone.0068451

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


Introduction

Exosomes are secreted nanovesicles (30–100 nm diameter) formed through the inward budding of multivesicular bodies (MVBs) that traffic and transfect proteins, mRNAs and miRNAs into target cells [1]. The significance of exosomal signaling in diverse aspects of physiology and pathophysiology has only recently been recognized [2]. Exosomes have now been reported to display immunomodulatory activity [3], [4] containing molecules such as HLA-G5, B7–H1, B7–H3 [5] and syncytian-1 [6] from trophoblast cells, suppression and activation of natural killer cells and macrophages [7], [8]; promote cell migration and metastasis [9], [10], traffic hydrophobic mediators of cell differentiation [11] and viral proteins [12]; and promote allograft survival and induce donor specific allograft tolerance [13]. Of particular relevance to this study, exosomes released from progenitor cells stimulate: endothelial cell migration [14]; tissue vascularization and angiogenesis [15], [16]; induce cell proliferation [17]; and are cardioprotective of ischemia/reperfusion injury [18]. Mesenchymal stem cells are archetypal multipotent progenitor cells that display fibroblastic morphology and plasticity to differentiate into diverse cell types including: osteocytes, adipocytes and endothelial cells. MSCs are isolated from various sources including bone marrow (principal source), adipose tissue and placenta. Within the human placenta, MSC have been isolated from umbilical cord blood and chorionic villi [19], [20] displaying phenotypes comparable to those isolated from bone marrow, including surface antigen expression (CD45−, CD14−, CD19−, CD80+, CD86+, CD40+ and B7H2+) and the capacity to differentiate into multiple linages in vitro. MSC have been implicated in wound healing and display the ability to migrate to sites of injury and engage in tissue repair and regeneration of bone, cartilage, liver tissue or myocardial cells [21], [22]. MSC modulate immune responses in collagen disease, multiple sclerosis and transplants bone marrow and contribute to vasculogenesis, angiogenesis and endothelial repair [23], processes that are fundamental for tissue repair. MSC affect tissue repair through the release of paracrine mediators [24]–[27] including exosomes [28]. MSCs are present in the first trimester human placenta, however, their role in placental vascular development remains to be established. During early pregnancy, the placental vasculature develops under hypoxic conditions. During the first trimester, placental PO2 is ∼ 2.6% before placento-maternal perfusion is established. At around 12 weeks of pregnancy, the placenta is perfused with maternal blood and PO2 increases to ∼ 8% [29], [30]. There is a paucity of information about the role of MSC and, in particular, the release of exosomes from MSC during this critical period of vascular development. Of note, however, Hofmann et al., [31], recently proposed that exosomes may function as part of an oxygen sensing mechanism that promotes vasculogenesis and angiogenesis. We hypothesize that: (i) exosomes released by pMSC act paracellularly to promote cell migration and angiogenesis within the placental villus tree; and (ii) that the release of exosomes from pMSC is responsive to changes in oxygen tension. The aim of this study, therefore, was to establish the effect of oxygen tension on the release of exosomes from pMSC; and the effects of pMSC-derived exosomes on the migration and angiogenic tube formation of human placental microvascular endothelial cells (hPMEC). pMSC-derived exosomes promote hPMEC cell migration and tube formation in vitro. The release and bioactivity of pMSC-derived exosomes is oxygen tension dependent. The data obtained are consistent with the hypothesis that pMSC-derived exosomes are released under hypoxic conditions and promote angiogenesis within the developing placenta.

Materials and Methods

First Trimester and Term Placental Collection

Tissue collection was approved by the Human Research Ethics Committees of the Royal Brisbane and Women’s Hospital, and the University of Queensland (HREC/09/QRBW/14). All experiments and data collection and analyses were conducted with an ISO 17025 and 21 CFR part 11 conforming laboratory environment. Written informed consent was obtained from women for the use of placental tissue for research purposes after clinically indicated termination of pregnancy in compliance with national research guidelines.

Isolation of Placental Mesenchymal Stem Cells

pMSC were isolated, from placental villi by enzymatic digestion using protocols adapted from Steigman & Fauza [32]. Briefly, placental chorionic villi (n = 6; 8–12 weeks gestational age) were separated from the remainder of the placenta unit and were washed in PBS. The villi were minced into small pieces and were transferred in to 50 ml tubes. The tissues were enzymatic digestion with dispase (2.4 U/ml) and collagenase (240 U/ml) made in PBS. The tissues were digested for 1 hr at 37°C on a rocker. The single cell suspension was then filtered through a 100 µm mesh into a new tube. The cells were centrifuged for 15 mins at 500×g at RT and the pellet was resuspended in 10 ml cDMEM. pMSC were cultured in Dulbecco’s modified Eagle’s medium (DMEM) (Life Technologies™, Carlsbad, CA), supplemented with 10% fetal bovine serum, 100 IU/mL penicillin, and 100 µg/mL streptomycin (Life Technologies™), at 37°C with 5% CO2. pMSC were characterised by well-established cell surface markers. All cells used in this study were passaged less than 6.

MSC Differentiation Assays

The differentiation potential of placental villi MSC was established according to previously published methods [33]. For adipogenesis, 2×105 pMSC were seeded in 6 well plates until confluent and differentiation was induced by indomethacin (60 µM) dexamethasone (1 µm), insulin (5 µg/ml) and isobutylmethylxanthine (IBMX) (0.5 mM). After 21 days, cells were fixed with 10% formalin and stained with Oil Red O. Adipogenic differentiation was determined by the appearance of Oil Red O. Osteogenic differentiation was induced by culturing 3×105 cells in 6 well plates in the presence of osteogenic induction media containing dexamethasone (0.1 µM), β-glycerol phosphate (10 mM) and L-ascorbate-2-phosphate (0.2 mM) for 21 days. Cells were fixed in 10% formalin and stained with Alizarin red. Differentiation was determined by the appearance of red deposits, representing areas of mineralized calcium. All reagents were from Sigma-Aldrich. Staining for both adipogenic and osteogenic assays was visualized using bright field phase contrast microscopy.

Isolation of hPMEC

The effects of exosomes on endothelial cell migration and angiogenesis were assessed using human placenta microvascular endothelial cells (hPMEC). hPMEC were isolated as previously described [34]. In brief, chorionic villi obtained from placental tissue samples (∼4 cm3 of the chorionic villous) were digested with trypsin/EDTA (0.25/0.2%, 20 min, 37°C) followed by 0.1 mg/ml collagenase (2 h, 37°C, Type II Clostridium histolyticum; Boehringer, Mannheim, Germany) in medium 199 (M199, Gibco Life Technologies, Carlsbad, CA, USA) Digested tissue was resuspended in M199 containing 5 mM D-glucose, 20% newborn calf serum (NBCS), 20% fetal calf serum (FCS), 3.2 mM L-glutamine and 100 U/ml penicillin streptomycin (primary culture medium, PCM), and filtered through a 55 µm pore size Nylon mesh. Filtered cell suspension was transferred into a 1% gelatin-coated T25 culture flask for culture (37°C, 5% O2, 5% CO2) in PCM. After 5 days, confluent cells were trypsinized (trypsin/EDTA 0.25/0.2%, 3 min, 37°C) and subjected to CD31 (against platelet endothelial cell adhesion molecule 1, PECAM-1)-positive immunoselection using Dynabeads CD31 microbeads from MACS® (Miltenyi Biotech, Bergisch-Gladbach, Germany). Endothelial cells immunoselection was performed mixing anti-CD31 antibody-magnetic coated microbeads with the cell suspension (48×103 beads/ml cell suspension, 20 min, 4°C). Suspension medium was discarded and cells attached to the magnetic microbeads were collected and washed (3 times) in HBSS (37°C). CD31-coated microbead-attached cells were resuspended in PCM containing 10% NBCS and 10% FCS, and cultured under standard conditions (37°C, 5% CO2) until confluence in passage 3. Immunocytochemistry analysis established that more than 96% of cells in the endothelial preparations used in the present study, were positive for von Willebland Factor (vWF) and CD31 (data not shown).

Flow Cytometry

The expression of cell surface and intracellular antigens was assessed by flow cytometry (FACScalibur™, Becton Dickinson, San Jose, CA, USA). To identify intra-cellular antigens, cells were detached, blocked with 1% bovine serum albumin (BSA; Sigma, St. Louis, MO) in phosphate buffered saline (PBS, Life Technologies™) then fixed with 0.01% paraformaldehyde (PFA) (Sigma) and permeabilized with 0.5% Triton X-100. To characterize the expression of cell surface and intracellular antigens, cells were detached and blocked with 1% BSA and incubated with specific anti-human primary antibodies, either conjugated with PE, FITC or PE-Cy5 or unconjugated. For unconjugated antibodies, cells were subsequently washed with 1% BSA and incubated with secondary goat anti-murine IgM PE (Santa Cruz Biotechnology®, Santa Cruz, CA, USA). All samples were analyzed in triplicate by FACScalibur™ flow cytometry (Becton Dickinson). Positive controls were hESC and negative controls were IgG or IgM primary antibody-specific isotype controls.

Hypoxia

The effects of oxygen tension on the release of exosomes from pMSC were assessed by incubating cells for 48 h (in exosome-free culture medium) under an atmosphere of 5% CO2-balanced N2 to obtain 1%, 3% or 8% O2 (pO2 ∼6.75, ∼20.25 or ∼54 mmHg, respectively) in an automated PROOX 110-scaled hypoxia chamber (BioSpherics™, Lacona, NY, USA). Cell number and viability was determined after each experimental treatment by Trypan Blue exclusion and Countess® Automated cell counter (Life Technologies™). Proliferation data was collected for all the experimental conditions and in particular to assess the effects of proliferation hypoxic conditions using a real-time cell imaging system (IncuCyte™ live-cell ESSEN BioScience Inc, Ann Arbor, Michigan, USA). In all experiments, viability remained at >95%. Incubation media pO2 and pH were independently confirmed using a blood gas analyzer (Radiometer®, Brønshøj, Denmark) and NeoFox oxygen probe (Ocean Optics ™, Dunedin, FL, USA). HIF expression was used in Western blot analysis as a positive control for hypoxia in MSC (data not show).

Isolation and Purification of pMSC Exosomes

Exosomes were isolated from cell-free pMSC as previously described [35]. In brief, pMSC-conditioned media was centrifuged at 300×g for 15 min, 2000×g for 30 min, and 12000×g for 45 min to remove whole cells and debris. The resultant supernatant were passed through a 0.22 µm filter sterilize Steritop™ (Millipore, Billerica, MA, USA) and then centrifuged at 100,000×g for 75 min (Thermo Fisher Scientific Ins., Asheville, NC, USA, Sorvall, SureSpin™ 630/36, fixed angle rotor). The pellet was resuspended in PBS, washed and re-centrifuged (100,000×g, 75 min). The pellet was resuspended in PBS, layered on a cushion of 30% (w/v) sucrose and centrifuged at 110,000 g for 75 min. The fraction containing pMSC exosomes (∼3.5 ml, 1.1270 density using OPTi digital refractometer (Bellingham+Stanley Inc., Lawrenceville, GA, USA) was recovered with an 18-G needle and diluted in PBS, and then ultracentrifuged at 110 000×g of 70 min. Recovered exosomes were resuspended in 50 µl PBS and their protein contents were determined using the Bradford assay (Bio-Rad DC) [35]. Exosome samples (5 µl) were prepared by adding RIPA buffer (50 mM Tris, 1% Triton×100, 0.1% SDS, 0.5% DOC, 1 mM EDTA, 150 mM NaCl, protease inhibitor) directly to exosomes suspended in PBS and sonicated at 37°C for 15 s three times to lyse exosome membrane and solubilise the proteins. Bovine serum albumin (BSA) diluted in RIPA buffer and PBS mixture (1∶1) were prepared as protein standards (0, 200, 400, 600, 800, 1000, 1500 µg/mL). Standards and samples (exosomes) were transferred to 96-well plates and procedures outlined by the manufacture were followed. In brief, alkaline copper tartrate solution (BIO-RAD, USA) and dilute Folin Reagent (BIO-RAD, USA) were added to the samples and incubated for 15 min. The absorbance was read at 750 nm with Paradigm Detection Platform (Beckman Coulter, USA).

Transmission Electron Microscopy

The exosome fraction isolated by differential and buoyant density gradient centrifugation was assessed by transmission electron microscopy. Exosome pellets (as described above) were fixed in 3% (w/v) glutaraldehyde and 2% paraformaldehyde in cacodylate buffer, pH 7.3. Five microlitres of sample was then applied to a continuous carbon grid and negatively stained with 2% uranyl acetate. The samples were examined in an FEI Tecnai 12 transmission electron microscope (FEI™, Hillsboro, Oregon, USA).

Western Blot

Exosome proteins separated by polyacrylamide gel electrophoresis were transferred to Immobilon-®FL polyvinylidene difluoride membranes (Millipore, Billerica, MA, USA) and probed with primary mouse monoclonal anti-CD63 (1∶2000), anti-CD81 (1∶1500) or anti-CD9 (1∶1500) as previously described [35] for specific exosome markers. Membranes were washed in Tris buffer saline Tween, and incubated (1 h) in TBST/0.2% BSA containing horseradish peroxidase-conjugated goat anti-mouse antibody. Proteins were detected by enhanced chemiluminescence with the SRX-101A Tabletop Processor (Konica Minolta, Ramsey, NJ, USA). The relative intensity of the bands was determined by densitometry using the GS-800 Calibrated Densitometer (Bio-Rad Laboratories, Hercules, CA, USA).

Migration and Tube Formation Assay

To assess the effect of exosomes on endothelial cell tube formation, hPMEC were cultured in 96 or 48-well culture plates (Corning Life Science, Tewksbury, MA, USA) according to the manufacturer’s instructions and visualized using a real-time cell imaging system (IncuCyte™ live-cell ESSEN BioScience Inc, Ann Arbor, Michigan, USA). Cells were imaged every hour to monitor treatment-induced cell migration, tube formation, confluence and morphologic changes. Cell migration was assessed by scratch assays, in which, hPMEC were grown to confluence and then a scratch was made using a 96-pin WoundMaker™. The wells were washed with PBS to remove any debris and incubated in the presence of 0 (control) 5, 10 or 20 µg protein/ml of pMSC-derived exosome isolated from cells cultured under 1%, 3% or 8% O2. Wound images were automatically acquired and registered by the IncuCyte™ software system. Typical kinetic updates were recorded at 2 h intervals for the duration of the experiment (48 h). The data were then analysed using an integrated metric: Relative Wound density. For the tube formation assay, 48-well culture plates on ice were incubated with 144 µl of chilled BD Matrigel matrix (10 mg/ml) per well at 37°C for 60 min. hPMEC (6×104) were resuspended in culture medium with the indicated concentration of pMSC-derived exosomes (5, 10 or 20 µg/ml) and incubated for up to 24 h at 37°C. The number of networks formed was determined using the IncuCyte™ system.

Proliferation Assay

A real-time imaging system (IncuCyteTM) was used to measure cell proliferation using non-label cell monolayer confluence approach. pMSC confluence was measure before and after the treatment (1%, 3% and 8% O2, 48 h). IncuCyteTM provide the capability to acquire high quality, phase-contrast images and an integrated confluence metric as a surrogate for cell number [36]. We used similar approach for to determine the effect of pMSC-derived exosomes on hPMEC proliferation during the migration assay.

Proteomic Analysis of Exosomes by Mass Spectrometry (MS)

Isolated exosomes were solubilised in 8 M urea in 50 mM ammonium bicarbonate, pH 8.5, and reduced with DTT for 1 h. Proteins were then alkylated in 10 mM iodoacetic acid (IAA) for 1 h in the dark. The sample was diluted to 1∶10 with 50 mM ammonium bicarbonate and digested with trypsin (20 µg) at 37°C for 18 h. The samples were desalted by solid phase extraction using a STAGE tip protocol (Stop and go extraction tips for matrix-assisted laser desorption/ionization, nanoelectrospray, and LC/MS sample pretreatment in proteomics). The eluted peptides were dried by centrifugal evaporation to remove acetonitrile and redissolved in Solvent A. The resulting peptide mixture was analysed by Liquid Chromatography (LC)/Mass Spectrometry (MS) LC-MS/MS on a 5600 Triple TOF mass spectrometer (AB Sciex, Framingham, U.S.A.) equipped with an Eksigent Nanoflow binary gradient HPLC system and a nanospray III ion source. Solvent A was 0.1% formic acid in water and solvent B was 0.1% fomic acid in acetonitrile. MS/MS spectra were collected using Information Dependent Acquisition (IDA) using a survey scan (m/z 350–1500) followed by 25 data-dependent product ion scans of the 25 most intense precursor ions. The data were searched using MASCOT and Protein Pilot search engines.

Functional Analysis of Exosome Proteome

Proteins identified by MS/MS were analyzed by PANTHER (Protein Analysis THrough Evolutionary Relationships; http://www.pantherdb.org). This software allows the prediction of classify proteins (and their genes) in order to facilitate high-throughput analysis. The classified proteins were classified according to their biological process and molecular function. Differentially expressed proteins were analyzed further by bioinformatic pathway analysis (Ingenuity Pathway Analysis [IPA]; Ingenuity Systems, Mountain View, CA; www.ingenuity.com).

Statistical Analysis

Data are represented as mean ± SEM, with n = 6 different cells culture (i.e. biological replicates) of pMSC isolated from first trimester pregnancies and n = 4 different cell cultures (i.e biological replicates) of hPMEC isolated from term placenta. Comparisons between two and more groups were performed by means of unpaired Student’s t-test and analysis of variance (ANOVA), respectively. If the ANOVA demonstrated a significant interaction between variables, post hoc analyses were performed by the multiple-comparison Bonferroni correction test. Statistical significance was defined at least p<0.05.

Results

Characterization of Exosome from Placental Mesenchymal Stem Cells

Cell surface protein expression by pMSC was characterized using flow cytometric analysis. pMSC were labelled with monoclonal antibodies specific for markers indicated in each histogram (Figure 1A). pMSC isolated from first trimester placental villi were positive for CD29+, CD44+, CD73+, CD90+, CD105+ (top panel) and negative for hematopoietic and endothelial markers: CD11b-, CD14−, CD31−, CD34−, CD45− (lower panel). When pMSC were stimulated under adipogenic and osteogenic conditions, they showed characteristic of adipocytes (Figure 1B1; formation of lipid vacuoles) and osteoblast cells (Figure 1B2; red deposits, representing areas of mineralized calcium), respectively. The exosomal particulate fraction isolated from pMSC was examined under transmission electron microscopy. Exosomes were identified as small vesicles between 40–100 nm in a cup-shaped form (Figure 1C). The particulate fraction was further characterized by the expression of specific exosome markers: CD63; CD9; and CD81 by Western blot analysis (Figure 1D).
Figure 1

Characterisation of exosomes from placental mesenchymal stem cell (pMSC).

Cells were isolated from chorionic villi obtained from first trimester pregnancy and cultured under standard conditions. Exosomes were isolated from pMSC supernatant as was indicated in Methods. (A) Representative flow cytometry histogram of pMSC labeled with positive markers such as CD29, CD44, CD73, CD90 and CD105 (top panel) or negative markers such as CD11b, CD14, CD31, CD34 and CD45 (bottom panel). Black solid peaks represent the isotype controls and the red solid peak represents the marker indicated. (B) Mulit differntiation potential of first trimester placental chorionic villi. 1, Adipogenesis was determined using oil red O staining of lipid droplets after 21 days in adipogenic media. 2, Osteogenesis was determined using alizarin red staining for the mineral matrix deposition after 21 days in osteogenic media. (C) Electron micrograph of exosomes isolated by ultracentrifuge from pMSC. (D) pMSC were exposed to 1%, 3% or 8% O2 during 48 hours and then exosomes proteins were isolated. Samples in each condition were analyzed by western blot after the separation of 20 ug of exosomes protein (same amount of exosome protein lead) for the presence of CD63, CD9 and CD81. In B, Scale bar 100 nm.

Characterisation of exosomes from placental mesenchymal stem cell (pMSC).

Cells were isolated from chorionic villi obtained from first trimester pregnancy and cultured under standard conditions. Exosomes were isolated from pMSC supernatant as was indicated in Methods. (A) Representative flow cytometry histogram of pMSC labeled with positive markers such as CD29, CD44, CD73, CD90 and CD105 (top panel) or negative markers such as CD11b, CD14, CD31, CD34 and CD45 (bottom panel). Black solid peaks represent the isotype controls and the red solid peak represents the marker indicated. (B) Mulit differntiation potential of first trimester placental chorionic villi. 1, Adipogenesis was determined using oil red O staining of lipid droplets after 21 days in adipogenic media. 2, Osteogenesis was determined using alizarin red staining for the mineral matrix deposition after 21 days in osteogenic media. (C) Electron micrograph of exosomes isolated by ultracentrifuge from pMSC. (D) pMSC were exposed to 1%, 3% or 8% O2 during 48 hours and then exosomes proteins were isolated. Samples in each condition were analyzed by western blot after the separation of 20 ug of exosomes protein (same amount of exosome protein lead) for the presence of CD63, CD9 and CD81. In B, Scale bar 100 nm.

Effect of Oxygen Tension on Exosome Release

To determine the effects of oxygen tension on the release of exosomes from pMSC, cells were incubated under atmospheres of 1%, 3% or 8% O2 and the exosomes released were quantified (as total exosomal protein µg/106 pMSC). Under these conditions, exosomal protein release averaged 2.8±0.27, 1.6±0.28 and 0.46±0.01 µg protein/106 pMSC, respectively. Exosome release from pMSC was significantly inversely correlated to oxygen tension (ANOVA, p<0.001, n = 5; Figure 2A). Furthermore, the relative abundance of the specific exosome marker CD63 in this particulate fraction displayed a similar inverse correlation to oxygen tension, as assessed by Western blot (Figure 2B). During the time course of these experiments, cell proliferation was not significantly affected by oxygen tension (i.e. 1%, 3% or 8% O2) (Figure 2C). The effect of oxygen tension on exosome release was not associated with a decrease in cell viability (Figure 2D).
Figure 2

The level of pMSC-derived exosomes compared to low oxygen tension.

Exosomes were isolated from pMSC supernatant exposed to 1%, 3% or 8% oxygen per 48 h. (A) Levels of exosomes are presented as protein concentration from 1×106 pMSC cell. (B) Same volume of exosome pellet loaded and analyzed by western blot for CD63 and β-actin in exosome from pMSC and cells, respectively. Lower panel: CD63/β-actin ratio densitometries from data in top panel normalized to 1 in 1% O2. (C) Effect of low oxygen tension on pMSC proliferation. (D) Trypan blue dye exclusion test to show residual pMSC cell viability exposed to 1%, 3% or 8% O2. Values are mean ± SEM. In A and B, *P<0.001 versus all condition; † p<0.001 versus 8% O2.

The level of pMSC-derived exosomes compared to low oxygen tension.

Exosomes were isolated from pMSC supernatant exposed to 1%, 3% or 8% oxygen per 48 h. (A) Levels of exosomes are presented as protein concentration from 1×106 pMSC cell. (B) Same volume of exosome pellet loaded and analyzed by western blot for CD63 and β-actin in exosome from pMSC and cells, respectively. Lower panel: CD63/β-actin ratio densitometries from data in top panel normalized to 1 in 1% O2. (C) Effect of low oxygen tension on pMSC proliferation. (D) Trypan blue dye exclusion test to show residual pMSC cell viability exposed to 1%, 3% or 8% O2. Values are mean ± SEM. In A and B, *P<0.001 versus all condition; † p<0.001 versus 8% O2.

Effect of pMSC-derived Exosomes on Cell Migration

The effects of exosomes (5, 10 or 20 µg protein/ml) isolated from pMSC cultured under 1%, 3% or 8% O2 on hPMEC migration are presented in Figure 3 A, C and E. pMSC exosomes significantly increased hPMEC migration in a time- and dose-dependent manner (p<0.005, n = 6). In addition, the effect on hPMEC migration was greater when exosomes were prepared from cells cultured under low oxygen tensions. Using the IncuCyte live cell imaging enabled non-invasive system, the cell proliferation based on area metric (confluence) was measurement. Exosomes isolated from pMSC cultures under 1% O2 increased significantly the hPMEC proliferation in ∼1.18-fold and ∼1,25-fold with 10 µg/ml and 20 µg/ml, respectively (Figure 4B). Furthermore, exosomes isolated from pMSC cultured under 3% and 8% O2 increased hPMEC proliferation in ∼1.21-fold and ∼1,18-fold using 20 µg/ml, respectively. We did not find significant effect of FBS-derived exosome on hPMEC migration and proliferation. Half-maximal stimulatory time (ST) and half-maximal stimulatory concentration (SC) values are presented in Table 1.
Figure 3

Exosomes increases cell migration in hPMEC.

hPMEC were grown to confluence in complete media, wound were made using 96 well WoundMaker and culture in absence (○) or presence (• 5, ▴ 10 or ▪ 20 µg/ml) of exosomal protein obtained from pMSC exposed to different oxygen tension. (A) Top: a, hPMEC image immediately after wounding; b, Graphical representation showing the calculation of initial wound width; c, Graphical representation of cell migration at the midpoint of the experiment. Bottom: The time course of the concentration-dependent effect of exosomal protein from 1% O2 on hPMEC, (C) 3% O2 or (E) 8% O2. (B) Area under curves from data in A, (D) from data in C, (F) from data in E. (G) Effect of pMEC-derived exosomes on hPMEC proliferation. Data represent an n = 6 well each point. Values are mean ± SEM. In B, D and F: *p<0.005 versus all condition; † P<0.005 versus 5 µg/ml; ‡ p<0.005 versus 10 µg/ml. In G, *p<0.005 versus control (−) with exo-pMSC from 1%, 3% or 8% O2; **p<0.001 versus control (−) with exo-pMSC from 1% O2.

Figure 4

Concentration response of exosomes on hPMEC migration.

Activation analysis of exosomes effect on hPMEC migration. Concentration response of exosomal protein from pMSC exposed to 1% (•), 3% (▪) or 8% (▴) O2 on hPMEC migration. Insert: half-maximal stimulatory concentration (SC50) at 6 h. Data represent an n = 6 well each point. Values are mean ± SEM. Insert: *p<0.001 versus all condition; † p<0.005 versus 8% O2.

Table 1

Kinetic characteristic of exosome effects on hPMEC migration.

Condition Parameter
Exosome [µg/ml) ST 50
Control9.9±0.19
1% O2 57.9±0.19*
104.0±0.18*
203.9±0.15*
3% O2 58.0±0.25*
106.2±0.30*
205.9±0.21*
8% O2 58.2±0.18*
107.8±0.17*
206.4±0.21*

The effect of exosomes isolated from pMSC-conditioned media on hPMEC in vitro migration. Data are expressed as half-maximal Stimulatory Time (ST 50 in hours) and represent the mean ± SEM. Primary cultures of endothelial cells were exposed (24 h) to increasing concentration of exosome (0, 5, 10 or 20 µg exosomal protein/ml) obtained from placental mesenchymal stem cell exposed to 1%, 3% or 8% O2. hPMEC (CD31+) were used in passage 3 for migration assay. *p<0.005 versus control; † P<0.005 versus all condition for ST 50.

Exosomes increases cell migration in hPMEC.

hPMEC were grown to confluence in complete media, wound were made using 96 well WoundMaker and culture in absence (○) or presence (• 5, ▴ 10 or ▪ 20 µg/ml) of exosomal protein obtained from pMSC exposed to different oxygen tension. (A) Top: a, hPMEC image immediately after wounding; b, Graphical representation showing the calculation of initial wound width; c, Graphical representation of cell migration at the midpoint of the experiment. Bottom: The time course of the concentration-dependent effect of exosomal protein from 1% O2 on hPMEC, (C) 3% O2 or (E) 8% O2. (B) Area under curves from data in A, (D) from data in C, (F) from data in E. (G) Effect of pMEC-derived exosomes on hPMEC proliferation. Data represent an n = 6 well each point. Values are mean ± SEM. In B, D and F: *p<0.005 versus all condition; † P<0.005 versus 5 µg/ml; ‡ p<0.005 versus 10 µg/ml. In G, *p<0.005 versus control (−) with exo-pMSC from 1%, 3% or 8% O2; **p<0.001 versus control (−) with exo-pMSC from 1% O2.

Concentration response of exosomes on hPMEC migration.

Activation analysis of exosomes effect on hPMEC migration. Concentration response of exosomal protein from pMSC exposed to 1% (•), 3% (▪) or 8% (▴) O2 on hPMEC migration. Insert: half-maximal stimulatory concentration (SC50) at 6 h. Data represent an n = 6 well each point. Values are mean ± SEM. Insert: *p<0.001 versus all condition; † p<0.005 versus 8% O2. The effect of exosomes isolated from pMSC-conditioned media on hPMEC in vitro migration. Data are expressed as half-maximal Stimulatory Time (ST 50 in hours) and represent the mean ± SEM. Primary cultures of endothelial cells were exposed (24 h) to increasing concentration of exosome (0, 5, 10 or 20 µg exosomal protein/ml) obtained from placental mesenchymal stem cell exposed to 1%, 3% or 8% O2. hPMEC (CD31+) were used in passage 3 for migration assay. *p<0.005 versus control; † P<0.005 versus all condition for ST 50. Exosome activation was concentration dependent for each condition (half-maximal stimulatory concentration (SC 50) = 4.2±0,5 from 1% O2: versus 5.9±0.6 and 12±1.2 µg/ml from 3% and 8% O2, respectively) (Figure 4).

Effect of pMSC-derived Exosomes on in vitro Tube Formation

In vitro angiogenic tube formation assays were used as a surrogate endpoint to assess the angiogenic effects of pMSC-derived exosomes. pMSC-derived exosomes significantly increased tube formation by hPMEC in a dose- and time-dependent manner when compared to vehicle-treated cells (p<0.005, Figure 5A) and inversely correlated to oxygen tension. In addition, exosome-induced tube formation was significantly greater when exosomes were prepared from cells grown under low oxygen tensions (Figure 5A). Half-maximal stimulatory time was 4.71±0.66, 11.50±0.25 and 35.96±0.5 µg/ml for exosomes treatment from pMSC exposed to 1%, 3% and 8% oxygen, respectively.
Figure 5

Exosomes from hypoxia increases microvascular tube formation in a dose-dependent manner.

hPMEC were incubated in Matrigel in absence or presence of different exosomal protein concentration from pMSC exposed to 1%, 3% or 8% O2. (A) Quantitative analysis of the total tube formation. (B) Concentration response from data in A. insert: half-maximal stimulatory concentration (SC50) at 16 h. Values are mean ± SEM. In A, **p<0.001 versus all condition; *p<0.005 versus corresponding values in 5 µg/ml, † p<0.005 versus corresponding values in 10 or 5 µg/ml. In B, *P<0.005 versus all values; † p<0.005 versus values in 8% O2.

Exosomes from hypoxia increases microvascular tube formation in a dose-dependent manner.

hPMEC were incubated in Matrigel in absence or presence of different exosomal protein concentration from pMSC exposed to 1%, 3% or 8% O2. (A) Quantitative analysis of the total tube formation. (B) Concentration response from data in A. insert: half-maximal stimulatory concentration (SC50) at 16 h. Values are mean ± SEM. In A, **p<0.001 versus all condition; *p<0.005 versus corresponding values in 5 µg/ml, † p<0.005 versus corresponding values in 10 or 5 µg/ml. In B, *P<0.005 versus all values; † p<0.005 versus values in 8% O2.

Proteomic Analysis of pMSC-derived Exosome

Mass spectrometry analysis identified over 200 exosomal proteins (Table 2). Data were subjected to ontology and pathway analysis using Panther and Gene Ontology algorithms and classified based on biological process and molecular function (Figure 6). In biological process, the most clusters identified were: cellular processes, cell communication, developmental and transport (Figure 6A). In molecular functions, the proteins related to binding and catalytic activity were the greatest recognized (Figure 6B). IPA analysis identified 157 proteins only present in exo-pMSC-1%O2 versus 34 and 37 individual proteins present in exo-pMSC-3%O2 and exo-pMSC-8%O2, respectively.(Figure 7A). Finally, the canonical pathways associated with our proteins defined by IPA Core analysis and related with cell migration were: actin cytoskeleton signaling, growth hormone signaling, clathrin-mediated endocytosis signaling, and VEGF signaling (Figure 7B-E). Furthermore, canonical pathways were associated with highest protein number in exosomes isolated from pMSC exposed to 1% O2 versus 3% and 8% O2.
Table 2

List of proteins identified in exosomes from pMSC exposed to different oxygen level.

Exo-pMSC-1%O2
IDSymbolEntrez Gene NameLocationType(s)
A2MG_HUMANA2Malpha-2-macroglobulinExtracellular Spacetransporter
ACTS_HUMANACTA1actin, alpha 1, skeletal muscleCytoplasmother
ACTB_HUMANACTBactin, betaCytoplasmother
ACTN1_HUMANACTN1actinin, alpha 1Cytoplasmother
SAHH_HUMANAHCYadenosylhomocysteinaseCytoplasmenzyme
FETUA_HUMANAHSGalpha-2-HS-glycoproteinExtracellular Spaceother
AIM1_HUMANAIM1absent in melanoma 1Extracellular Spaceother
ALBU_HUMANALBalbuminExtracellular Spacetransporter
ALDOA_HUMANALDOAaldolase A, fructose-bisphosphateCytoplasmenzyme
AMOL2_HUMANAMOTL2angiomotin like 2Plasma Membraneother
ANXA1_HUMANANXA1annexin A1Plasma Membraneother
ANXA2_HUMANANXA2annexin A2Plasma Membraneother
ANXA5_HUMANANXA5annexin A5Plasma Membraneother
APOA1_HUMANAPOA1apolipoprotein A-IExtracellular Spacetransporter
APOB_HUMANAPOBapolipoprotein B (including Ag(x) antigen)Extracellular Spacetransporter
APOC3_HUMANAPOC3apolipoprotein C-IIIExtracellular Spacetransporter
APOE_HUMANAPOEapolipoprotein EExtracellular Spacetransporter
ARF5_HUMANARF5ADP-ribosylation factor 5Cytoplasmenzyme
ARHG2_HUMANARHGEF2Rho/Rac guanine nucleotide exchange factor (GEF) 2Cytoplasmother
ARPC3_HUMANARPC3actin related protein 2/3 complex, subunit 3, 21 kDaCytoplasmother
ASB18_HUMANASB18ankyrin repeat and SOCS box containing 18unknownother
ASH1L_HUMANASH1Lash1 (absent, small, or homeotic)-like (Drosophila)Nucleustranscription regulator
A16L1_HUMANATG16L1autophagy related 16-like 1 (S. cerevisiae)Cytoplasmother
AT8B1_HUMANATP8B1ATPase, aminophospholipid transporter, class I, type 8B, member 1Plasma Membranetransporter
ATRN_HUMANATRNattractinExtracellular Spaceother
B3GN1_HUMANB3GNT1UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 1Cytoplasmenzyme
BCL3_HUMANBCL3B-cell CLL/lymphoma 3Nucleustranscription regulator
BCDO1_HUMANBCMO1beta-carotene 15,15′-monooxygenase 1Cytoplasmenzyme
BEND5_HUMANBEND5BEN domain containing 5Cytoplasmother
BMP1_HUMANBMP1bone morphogenetic protein 1Extracellular Spacepeptidase
CJ118_HUMANC10orf118chromosome 10 open reading frame 118unknownother
C1QT3_HUMANC1QTNF3C1q and tumor necrosis factor related protein 3Extracellular Spaceother
CO3_HUMANC3complement component 3Extracellular Spacepeptidase
CO5_HUMANC5complement component 5Extracellular Spacecytokine
CI114_HUMANC9orf114chromosome 9 open reading frame 114Nucleusother
CALRL_HUMANCALCRLcalcitonin receptor-likePlasma MembraneG-protein coupled receptor
CAMP2_HUMANCAMSAP2calmodulin regulated spectrin-associated protein family, member 2unknownother
CAND1_HUMANCAND1cullin-associated and neddylation-dissociated 1Cytoplasmtranscription regulator
CC147_HUMANCCDC147coiled-coil domain containing 147Extracellular Spaceother
CB077_HUMANCCDC173coiled-coil domain containing 173unknownother
CCD60_HUMANCCDC60coiled-coil domain containing 60unknownother
CCD73_HUMANCCDC73coiled-coil domain containing 73unknownother
CD44_HUMANCD44CD44 molecule (Indian blood group)Plasma Membraneenzyme
CD59_HUMANCD59CD59 molecule, complement regulatory proteinPlasma Membraneother
CDCA2_HUMANCDCA2cell division cycle associated 2Nucleusother
CFAH_HUMANCFHcomplement factor HExtracellular Spaceother
CGRF1_HUMANCGRRF1cell growth regulator with ring finger domain 1unknownother
CLCF1_HUMANCLCF1cardiotrophin-like cytokine factor 1Extracellular Spacecytokine
CNOT1_HUMANCNOT1CCR4-NOT transcription complex, subunit 1Cytoplasmother
COG2_HUMANCOG2component of oligomeric golgi complex 2Cytoplasmtransporter
COCA1_HUMANCOL12A1collagen, type XII, alpha 1Extracellular Spaceother
CO1A1_HUMANCOL1A1collagen, type I, alpha 1Extracellular Spaceother
CO1A2_HUMANCOL1A2collagen, type I, alpha 2Extracellular Spaceother
CO6A1_HUMANCOL6A1collagen, type VI, alpha 1Extracellular Spaceother
CO6A2_HUMANCOL6A2collagen, type VI, alpha 2Extracellular Spaceother
CO6A3_HUMANCOL6A3collagen, type VI, alpha 3Extracellular Spaceother
COMP_HUMANCOMPcartilage oligomeric matrix proteinExtracellular Spaceother
CBPA1_HUMANCPA1carboxypeptidase A1 (pancreatic)Extracellular Spacepeptidase
SDF1_HUMANCXCL12chemokine (C-X-C motif) ligand 12Extracellular Spacecytokine
DEN1A_HUMANDENND1ADENN/MADD domain containing 1APlasma Membraneother
MYCPP_HUMANDENND4ADENN/MADD domain containing 4ANucleusother
DYH9_HUMANDNAH9dynein, axonemal, heavy chain 9Cytoplasmother
DNJB4_HUMANDNAJB4DnaJ (Hsp40) homolog, subfamily B, member 4Nucleusother
DSCAM_HUMANDSCAMDown syndrome cell adhesion moleculePlasma Membraneother
EHD3_HUMANEHD3EH-domain containing 3Cytoplasmother
EMAL6_HUMANEML6echinoderm microtubule associated protein like 6unknownother
ENOA_HUMANENO1enolase 1, (alpha)Cytoplasmtranscription regulator
ENTP7_HUMANENTPD7ectonucleoside triphosphate diphosphohydrolase 7Cytoplasmenzyme
HYEP_HUMANEPHX1epoxide hydrolase 1, microsomal (xenobiotic)Cytoplasmpeptidase
FA10_HUMANF10coagulation factor XExtracellular Spacepeptidase
F13A_HUMANF13A1coagulation factor XIII, A1 polypeptideExtracellular Spaceenzyme
THRB_HUMANF2coagulation factor II (thrombin)Extracellular Spacepeptidase
FA5_HUMANF5coagulation factor V (proaccelerin, labile factor)Plasma Membraneenzyme
F117A_HUMANFAM117Afamily with sequence similarity 117, member Aunknowntransporter
F171B_HUMANFAM171Bfamily with sequence similarity 171, member Bunknownother
F208B_HUMANFAM208Bfamily with sequence similarity 208, member Bunknownother
FBLN1_HUMANFBLN1fibulin 1Extracellular Spaceother
FBN1_HUMANFBN1fibrillin 1Extracellular Spaceother
FIBA_HUMANFGAfibrinogen alpha chainExtracellular Spaceother
FGF3_HUMANFGF3fibroblast growth factor 3Extracellular Spacegrowth factor
FLNA_HUMANFLNAfilamin A, alphaCytoplasmother
FINC_HUMANFN1fibronectin 1Extracellular Spaceenzyme
FRPD3_HUMANFRMPD3FERM and PDZ domain containing 3unknownother
GALK1_HUMANGALK1galactokinase 1Cytoplasmkinase
G3P_HUMANGAPDHglyceraldehyde-3-phosphate dehydrogenaseCytoplasmenzyme
GSCR1_HUMANGLTSCR1glioma tumor suppressor candidate region gene 1Extracellular Spaceother
GBG12_HUMANGNG12guanine nucleotide binding protein (G protein), gamma 12Plasma Membraneenzyme
GRIN1_HUMANGPRIN1G protein regulated inducer of neurite outgrowth 1Plasma Membraneother
GELS_HUMANGSNgelsolinExtracellular Spaceother
TF2H1_HUMANGTF2H1general transcription factor IIH, polypeptide 1, 62 kDaNucleustranscription regulator
HBB_HUMANHBBhemoglobin, betaCytoplasmtransporter
HCN1_HUMANHCN1hyperpolarization activated cyclic nucleotide-gated potassium channel 1Plasma Membraneion channel
HTR5A_HUMANHEATR5AHEAT repeat containing 5Aunknownother
H13_HUMANHIST1H1Dhistone cluster 1, H1dNucleusother
H2B1M_HUMANHIST1H2BMhistone cluster 1, H2bmNucleusother
H31T_HUMANHIST3H3histone cluster 3, H3Nucleusother
HMMR_HUMANHMMRhyaluronan-mediated motility receptor (RHAMM)Plasma Membraneother
HS90A_HUMANHSP90AA1heat shock protein 90 kDa alpha (cytosolic), class A member 1Cytoplasmenzyme
ENPL_HUMANHSP90B1heat shock protein 90 kDa beta (Grp94), member 1Cytoplasmother
GRP78_HUMANHSPA5heat shock 70 kDa protein 5 (glucose-regulated protein, 78 kDa)Cytoplasmenzyme
PGBM_HUMANHSPG2heparan sulfate proteoglycan 2Plasma Membraneenzyme
HYDIN_HUMANHYDINHYDIN, axonemal central pair apparatus proteinunknownother
ALS_HUMANIGFALSinsulin-like growth factor binding protein, acid labile subunitExtracellular Spaceother
IGHM_HUMANIGHMimmunoglobulin heavy constant muPlasma Membranetransmembrane receptor
IGKC_HUMANIGKCimmunoglobulin kappa constantExtracellular Spaceother
IGSF8_HUMANIGSF8immunoglobulin superfamily, member 8Plasma Membraneother
IP6K3_HUMANIP6K3inositol hexakisphosphate kinase 3Cytoplasmkinase
ITB1_HUMANITGB1integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen CD29 includes MDF2, MSK12)Plasma Membranetransmembrane receptor
ITIH2_HUMANITIH2inter-alpha-trypsin inhibitor heavy chain 2Extracellular Spaceother
ITIH3_HUMANITIH3inter-alpha-trypsin inhibitor heavy chain 3Extracellular Spaceother
IRK2_HUMANKCNJ2potassium inwardly-rectifying channel, subfamily J, member 2Plasma Membraneion channel
KI20B_HUMANKIF20Bkinesin family member 20BNucleusenzyme
IMB1_HUMANKPNB1karyopherin (importin) beta 1Nucleustransporter
K2C1_HUMANKRT1keratin 1Cytoplasmother
K1C10_HUMANKRT10keratin 10Cytoplasmother
K22E_HUMANKRT2keratin 2Cytoplasmother
K1C39_HUMANKRT39keratin 39Cytoplasmother
K1C9_HUMANKRT9keratin 9Cytoplasmother
LAMB1_HUMANLAMB1laminin, beta 1Extracellular Spaceother
LDB1_HUMANLDB1LIM domain binding 1Nucleustranscription regulator
LG3BP_HUMANLGALS3BPlectin, galactoside-binding, soluble, 3 binding proteinPlasma Membranetransmembrane receptor
LHPL3_HUMANLHFPL3lipoma HMGIC fusion partner-like 3unknownother
CQ054_HUMANLINC00469long intergenic non-protein coding RNA 469unknownother
YA033_HUMANLOC339524uncharacterized LOC339524unknownother
LONM_HUMANLONP1lon peptidase 1, mitochondrialCytoplasmpeptidase
LONF2_HUMANLONRF2LON peptidase N-terminal domain and ring finger 2unknownother
LPAR6_HUMANLPAR6lysophosphatidic acid receptor 6Plasma MembraneG-protein coupled receptor
LRP1_HUMANLRP1low density lipoprotein receptor-related protein 1Plasma Membranetransmembrane receptor
TRFL_HUMANLTFlactotransferrinExtracellular Spacepeptidase
LUM_HUMANLUMlumicanExtracellular Spaceother
LY75_HUMANLY75lymphocyte antigen 75Plasma Membraneother
MACD1_HUMANMACROD1MACRO domain containing 1Cytoplasmenzyme
MAP2_HUMANMAP2microtubule-associated protein 2Cytoplasmother
MAST3_HUMANMAST3microtubule associated serine/threonine kinase 3unknownkinase
MED16_HUMANMED16mediator complex subunit 16Nucleustranscription regulator
MFGM_HUMANMFGE8milk fat globule-EGF factor 8 proteinExtracellular Spaceother
MKLN1_HUMANMKLN1muskelin 1, intracellular mediator containing kelch motifsCytoplasmother
MOES_HUMANMSNmoesinPlasma Membraneother
MTERF_HUMANMTERFmitochondrial transcription termination factorCytoplasmtranscription regulator
MYH9_HUMANMYH9myosin, heavy chain 9, non-muscleCytoplasmtransporter
MYL6_HUMANMYL6myosin, light chain 6, alkali, smooth muscle and non-muscleCytoplasmother
MYLK_HUMANMYLKmyosin light chain kinaseCytoplasmkinase
MY18B_HUMANMYO18Bmyosin XVIIIBCytoplasmother
NCTR1_HUMANNCR1natural cytotoxicity triggering receptor 1Plasma Membranetransmembrane receptor
NID1_HUMANNID1nidogen 1Extracellular Spaceother
NOL4_HUMANNOL4nucleolar protein 4Nucleusother
NOTC3_HUMANNOTCH3notch 3Plasma Membranetranscription regulator
NGBR_HUMANNUS1nuclear undecaprenyl pyrophosphate synthase 1 homolog (S. cerevisiae)Cytoplasmother
OGG1_HUMANOGG18-oxoguanine DNA glycosylaseNucleusenzyme
O51F1_HUMANOR51F1olfactory receptor, family 51, subfamily F, member 1Plasma MembraneG-protein coupled receptor
ORC5_HUMANORC5origin recognition complex, subunit 5Nucleusother
PDIA1_HUMANP4HBprolyl 4-hydroxylase, beta polypeptideCytoplasmenzyme
PDIA3_HUMANPDIA3protein disulfide isomerase family A, member 3Cytoplasmpeptidase
F261_HUMANPFKFB16-phosphofructo-2-kinase/fructose-2,6-biphosphatase 1Cytoplasmkinase
PGAM1_HUMANPGAM1phosphoglycerate mutase 1 (brain)Cytoplasmphosphatase
PI3R4_HUMANPIK3R4phosphoinositide-3-kinase, regulatory subunit 4Cytoplasmkinase
KPYM_HUMANPKMpyruvate kinase, muscleunknownkinase
PLCL1_HUMANPLCL1phospholipase C-like 1Cytoplasmenzyme
PLMN_HUMANPLGplasminogenExtracellular Spacepeptidase
PLPL8_HUMANPNPLA8patatin-like phospholipase domain containing 8Cytoplasmenzyme
POSTN_HUMANPOSTNperiostin, osteoblast specific factorExtracellular Spaceother
P2R3C_HUMANPPP2R3Cprotein phosphatase 2, regulatory subunit B”, gammaCytoplasmother
PREX1_HUMANPREX1phosphatidylinositol-3,4,5-trisphosphate-dependent Rac exchange factor 1Cytoplasmother
PRP31_HUMANPRPF31PRP31 pre-mRNA processing factor 31 homolog (S. cerevisiae)Nucleusother
PSA3_HUMANPSMA3proteasome (prosome, macropain) subunit, alpha type, 3Cytoplasmpeptidase
PSA7L_HUMANPSMA8proteasome (prosome, macropain) subunit, alpha type, 8Cytoplasmpeptidase
PSB5_HUMANPSMB5proteasome (prosome, macropain) subunit, beta type, 5Cytoplasmpeptidase
PSB6_HUMANPSMB6proteasome (prosome, macropain) subunit, beta type, 6Cytoplasmpeptidase
PSB7_HUMANPSMB7proteasome (prosome, macropain) subunit, beta type, 7Cytoplasmpeptidase
PTX3_HUMANPTX3pentraxin 3, longExtracellular Spaceother
PUSL1_HUMANPUSL1pseudouridylate synthase-like 1unknownenzyme
PZP_HUMANPZPpregnancy-zone proteinExtracellular Spaceother
ARIP4_HUMANRAD54L2RAD54-like 2 (S. cerevisiae)Nucleustranscription regulator
RFX8_HUMANRFX8regulatory factor X, 8unknownother
RGPD3_HUMANRGPD5 (includes others)RANBP2-like and GRIP domain containing 5Nucleusother
RHPN2_HUMANRHPN2rhophilin, Rho GTPase binding protein 2Cytoplasmother
RIMKA_HUMANRIMKLAribosomal modification protein rimK-like family member Aunknownother
RN217_HUMANRNF217ring finger protein 217unknownenzyme
RL35_HUMANRPL35ribosomal protein L35Cytoplasmother
S10AB_HUMANS100A11S100 calcium binding protein A11Cytoplasmother
SACS_HUMANSACSspastic ataxia of Charlevoix-Saguenay (sacsin)Nucleusother
SALL4_HUMANSALL4sal-like 4 (Drosophila)Nucleusother
SDCB1_HUMANSDCBPsyndecan binding protein (syntenin)Plasma Membraneenzyme
SEM4G_HUMANSEMA4Gsema domain, immunoglobulin domain (Ig), transmembrane domain (TM) and short cytoplasmic domain, (semaphorin) 4GPlasma Membraneother
SEM6D_HUMANSEMA6Dsema domain, transmembrane domain (TM), and cytoplasmic domain, (semaphorin) 6DPlasma Membraneother
SPB10_HUMANSERPINB10serpin peptidase inhibitor, clade B (ovalbumin), member 10Cytoplasmother
ANT3_HUMANSERPINC1serpin peptidase inhibitor, clade C (antithrombin), member 1Extracellular Spaceother
PEDF_HUMANSERPINF1serpin peptidase inhibitor, clade F (alpha-2 antiplasmin, pigment epithelium derived factor), member 1Extracellular Spaceother
A2AP_HUMANSERPINF2serpin peptidase inhibitor, clade F (alpha-2 antiplasmin, pigment epithelium derived factor), member 2Extracellular Spaceother
SH3L3_HUMANSH3BGRL3SH3 domain binding glutamic acid-rich protein like 3Nucleusother
S12A7_HUMANSLC12A7solute carrier family 12 (potassium/chloride transporters), member 7Plasma Membranetransporter
S13A4_HUMANSLC13A4solute carrier family 13 (sodium/sulfate symporters), member 4Plasma Membranetransporter
SL9C2_HUMANSLC9C2solute carrier family 9, member C2 (putative)unknownother
SNTB2_HUMANSNTB2syntrophin, beta 2 (dystrophin-associated protein A1, 59 kDa, basic component 2)Plasma Membraneother
SPAT7_HUMANSPATA7spermatogenesis associated 7unknownother
STAB2_HUMANSTAB2stabilin 2Plasma Membranetransmembrane receptor
ST3L1_HUMANSTAG3L1stromal antigen 3-like 1unknownother
TBL2_HUMANTBL2transducin (beta)-like 2Plasma Membraneother
TBPL1_HUMANTBPL1TBP-like 1Nucleustranscription regulator
TBX20_HUMANTBX20T-box 20Nucleustranscription regulator
TRFE_HUMANTFtransferrinExtracellular Spacetransporter
THA11_HUMANTHAP11THAP domain containing 11Nucleusother
TSP1_HUMANTHBS1thrombospondin 1Extracellular Spaceother
THY1_HUMANTHY1Thy-1 cell surface antigenPlasma Membraneother
TIAR_HUMANTIAL1TIA1 cytotoxic granule-associated RNA binding protein-like 1Nucleustranscription regulator
TIMP1_HUMANTIMP1TIMP metallopeptidase inhibitor 1Extracellular Spaceother
TKT_HUMANTKTtransketolaseCytoplasmenzyme
TLN1_HUMANTLN1talin 1Plasma Membraneother
TENA_HUMANTNCtenascin CExtracellular Spaceother
TNAP3_HUMANTNFAIP3tumor necrosis factor, alpha-induced protein 3Nucleusenzyme
P53_HUMANTP53tumor protein p53Nucleustranscription regulator
TPIS_HUMANTPI1triosephosphate isomerase 1Cytoplasmenzyme
TPC12_HUMANTRAPPC12trafficking protein particle complex 12unknownother
TITIN_HUMANTTNtitinunknownkinase
TTYH3_HUMANTTYH3tweety homolog 3 (Drosophila)Plasma Membraneion channel
TBA1B_HUMANTUBA1Btubulin, alpha 1bCytoplasmother
TBB5_HUMANTUBBtubulin, beta class ICytoplasmother
TBB1_HUMANTUBB1tubulin, beta 1 class VICytoplasmother
TBB2A_HUMANTUBB2Atubulin, beta 2A class IIaCytoplasmother
TYK2_HUMANTYK2tyrosine kinase 2Plasma Membranekinase
UBQLN_HUMANUBQLNLubiquilin-likeunknownother
UD2A3_HUMANUGT2A3UDP glucuronosyltransferase 2 family, polypeptide A3Plasma Membraneenzyme
USMG5_HUMANUSMG5up-regulated during skeletal muscle growth 5 homolog (mouse)Cytoplasmother
VAT1_HUMANVAT1vesicle amine transport protein 1 homolog (T. californica)Plasma Membranetransporter
CSPG2_HUMANVCANversicanExtracellular Spaceother
VIME_HUMANVIMvimentinCytoplasmother
VTNC_HUMANVTNvitronectinExtracellular Spaceother
WWC2_HUMANWWC2WW and C2 domain containing 2unknownother
1433E_HUMANYWHAEtyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, epsilon polypeptideCytoplasmother
ZN268_HUMANZNF268zinc finger protein 268Nucleusother
ZN510_HUMANZNF510zinc finger protein 510Nucleusother
ZN516_HUMANZNF516zinc finger protein 516Nucleusother
ZN599_HUMANZNF599zinc finger protein 599unknownother
ZN729_HUMANZNF729zinc finger protein 729unknownother
ZNF74_HUMANZNF74zinc finger protein 74Nucleusother
Exo-pMSC-3%O2
ID Symbol Entrez Gene Name Location Type(s)
ABCA1_HUMANABCA1ATP-binding cassette, sub-family A (ABC1), member 1Plasma Membranetransporter
MRP1_HUMANABCC1ATP-binding cassette, sub-family C (CFTR/MRP), member 1Plasma Membranetransporter
ACTB_HUMANACTBactin, betaCytoplasmother
ADCK4_HUMANADCK4aarF domain containing kinase 4Cytoplasmkinase
FETA_HUMANAFPalpha-fetoproteinExtracellular Spacetransporter
FETUA_HUMANAHSGalpha-2-HS-glycoproteinExtracellular Spaceother
ALBU_HUMANALBalbuminExtracellular Spacetransporter
ARHG2_HUMANARHGEF2Rho/Rac guanine nucleotide exchange factor (GEF) 2Cytoplasmother
BMR1B_HUMANBMPR1Bbone morphogenetic protein receptor, type IBPlasma Membranekinase
BPTF_HUMANBPTFbromodomain PHD finger transcription factorNucleustranscription regulator
CJ118_HUMANC10orf118chromosome 10 open reading frame 118unknownother
ERG28_HUMANC14orf1chromosome 14 open reading frame 1Cytoplasmother
CH073_HUMANC8orf73chromosome 8 open reading frame 73unknownother
CCD80_HUMANCCDC80coiled-coil domain containing 80Nucleusother
MPIP1_HUMANCDC25Acell division cycle 25 homolog A (S. pombe)Nucleusphosphatase
CDA7L_HUMANCDCA7Lcell division cycle associated 7-likeNucleusother
CDK13_HUMANCDK13cyclin-dependent kinase 13Nucleuskinase
CNGA1_HUMANCNGA1cyclic nucleotide gated channel alpha 1Plasma Membraneion channel
COG2_HUMANCOG2component of oligomeric golgi complex 2Cytoplasmtransporter
CODA1_HUMANCOL13A1collagen, type XIII, alpha 1Plasma Membraneother
CO1A1_HUMANCOL1A1collagen, type I, alpha 1Extracellular Spaceother
DIAC_HUMANCTBSchitobiase, di-N-acetyl-Cytoplasmenzyme
DUPD1_HUMANDUPD1dual specificity phosphatase and pro isomerase domain containing 1unknownenzyme
RNZ2_HUMANELAC2elaC homolog 2 (E. coli)Nucleusenzyme
EPC2_HUMANEPC2enhancer of polycomb homolog 2 (Drosophila)unknownother
XPF_HUMANERCC4excision repair cross-complementing rodent repair deficiency, complementation group 4Nucleusenzyme
ERI2_HUMANERI2ERI1 exoribonuclease family member 2unknownother
ETS1_HUMANETS1v-ets erythroblastosis virus E26 oncogene homolog 1 (avian)Nucleustranscription regulator
EXTL2_HUMANEXTL2exostoses (multiple)-like 2Cytoplasmenzyme
FA10_HUMANF10coagulation factor XExtracellular Spacepeptidase
THRB_HUMANF2coagulation factor II (thrombin)Extracellular Spacepeptidase
F117A_HUMANFAM117Afamily with sequence similarity 117, member Aunknowntransporter
F168A_HUMANFAM168Afamily with sequence similarity 168, member Aunknownother
F208A_HUMANFAM208Afamily with sequence similarity 208, member Aunknownother
F210A_HUMANFAM210Afamily with sequence similarity 210, member ACytoplasmother
FBN1_HUMANFBN1fibrillin 1Extracellular Spaceother
FGF18_HUMANFGF18fibroblast growth factor 18Extracellular Spacegrowth factor
FINC_HUMANFN1fibronectin 1Extracellular Spaceenzyme
FNIP2_HUMANFNIP2folliculin interacting protein 2Cytoplasmother
VTDB_HUMANGCgroup-specific component (vitamin D binding protein)Extracellular Spacetransporter
GSCR1_HUMANGLTSCR1glioma tumor suppressor candidate region gene 1Extracellular Spaceother
GOG8A_HUMANGOLGA8A/GOLGA8Bgolgin A8 family, member BCytoplasmother
GRIN1_HUMANGPRIN1G protein regulated inducer of neurite outgrowth 1Plasma Membraneother
HBB_HUMANHBBhemoglobin, betaCytoplasmtransporter
HELZ_HUMANHELZhelicase with zinc fingerNucleusenzyme
HJURP_HUMANHJURPHolliday junction recognition proteinNucleusother
1B39_HUMANHLA-Bmajor histocompatibility complex, class I, BPlasma Membranetransmembrane receptor
H90B3_HUMANHSP90AB3Pheat shock protein 90 kDa alpha (cytosolic), class B member 3, pseudogeneunknownother
I22R1_HUMANIL22RA1interleukin 22 receptor, alpha 1Plasma Membranetransmembrane receptor
ITIH2_HUMANITIH2inter-alpha-trypsin inhibitor heavy chain 2Extracellular Spaceother
K2C1_HUMANKRT1keratin 1Cytoplasmother
K2C5_HUMANKRT5keratin 5Cytoplasmother
AMPL_HUMANLAP3leucine aminopeptidase 3Cytoplasmpeptidase
TRFL_HUMANLTFlactotransferrinExtracellular Spacepeptidase
MLAS1_HUMANMLLT4-AS1MLLT4 antisense RNA 1unknownother
MYH4_HUMANMYH4myosin, heavy chain 4, skeletal muscleCytoplasmenzyme
ULA1_HUMANNAE1NEDD8 activating enzyme E1 subunit 1Cytoplasmenzyme
NGEF_HUMANNGEFneuronal guanine nucleotide exchange factorCytoplasmother
NAL13_HUMANNLRP13NLR family, pyrin domain containing 13unknownother
NOL4_HUMANNOL4nucleolar protein 4Nucleusother
NTM1A_HUMANNTMT1N-terminal Xaa-Pro-Lys N-methyltransferase 1Nucleusenzyme
TEN3_HUMANODZ3odz, odd Oz/ten-m homolog 3 (Drosophila)Plasma Membraneother
O10A7_HUMANOR10A7olfactory receptor, family 10, subfamily A, member 7Plasma Membraneother
OSGEP_HUMANOSGEPO-sialoglycoprotein endopeptidaseunknownpeptidase
PGK1_HUMANPGK1phosphoglycerate kinase 1Cytoplasmkinase
PHF10_HUMANPHF10PHD finger protein 10Nucleusother
KCC1B_HUMANPNCKpregnancy up-regulated non-ubiquitously expressed CaM kinaseunknownkinase
P2R3C_HUMANPPP2R3Cprotein phosphatase 2, regulatory subunit B”, gammaCytoplasmother
PR38A_HUMANPRPF38APRP38 pre-mRNA processing factor 38 (yeast) domain containing ANucleusother
PTPRK_HUMANPTPRKprotein tyrosine phosphatase, receptor type, KPlasma Membranephosphatase
PUSL1_HUMANPUSL1pseudouridylate synthase-like 1unknownenzyme
PXDN_HUMANPXDNperoxidasin homolog (Drosophila)Extracellular Spaceenzyme
PXK_HUMANPXKPX domain containing serine/threonine kinaseCytoplasmkinase
PZP_HUMANPZPpregnancy-zone proteinExtracellular Spaceother
RAB10_HUMANRAB10RAB10, member RAS oncogene familyCytoplasmenzyme
REST_HUMANRESTRE1-silencing transcription factorNucleustranscription regulator
RFX8_HUMANRFX8regulatory factor X, 8unknownother
SALL4_HUMANSALL4sal-like 4 (Drosophila)Nucleusother
A2AP_HUMANSERPINF2serpin peptidase inhibitor, clade F (alpha-2 antiplasmin, pigment epithelium derived factor), member 2Extracellular Spaceother
SHSA7_HUMANSHISA7shisa homolog 7 (Xenopus laevis)unknownother
S12A7_HUMANSLC12A7solute carrier family 12 (potassium/chloride transporters), member 7Plasma Membranetransporter
S35A1_HUMANSLC35A1solute carrier family 35 (CMP-sialic acid transporter), member A1Cytoplasmtransporter
SMTN_HUMANSMTNsmoothelinExtracellular Spaceother
SPC25_HUMANSPC25SPC25, NDC80 kinetochore complex component, homolog (S. cerevisiae)Cytoplasmother
SPP24_HUMANSPP2secreted phosphoprotein 2, 24 kDaExtracellular Spaceother
SYNJ1_HUMANSYNJ1synaptojanin 1Cytoplasmphosphatase
TANC1_HUMANTANC1tetratricopeptide repeat, ankyrin repeat and coiled-coil containing 1Plasma Membraneother
TCEA3_HUMANTCEA3transcription elongation factor A (SII), 3Nucleustranscription regulator
TET1_HUMANTET1tet methylcytosine dioxygenase 1Nucleusother
TEX2_HUMANTEX2testis expressed 2unknownother
TRFE_HUMANTFtransferrinExtracellular Spacetransporter
TGFR1_HUMANTGFBR1transforming growth factor, beta receptor 1Plasma Membranekinase
TSP1_HUMANTHBS1thrombospondin 1Extracellular Spaceother
TITIN_HUMANTTNtitinunknownkinase
VAT1_HUMANVAT1vesicle amine transport protein 1 homolog (T. californica)Plasma Membranetransporter
MELT_HUMANVEPH1ventricular zone expressed PH domain homolog 1 (zebrafish)Nucleusother
VTNC_HUMANVTNvitronectinExtracellular Spaceother
XKR3_HUMANXKR3XK, Kell blood group complex subunit-related family, member 3unknownother
XPO5_HUMANXPO5exportin 5Nucleustransporter
ZDH19_HUMANZDHHC19zinc finger, DHHC-type containing 19unknownother
ZMYM4_HUMANZMYM4zinc finger, MYM-type 4unknownother
ZN143_HUMANZNF143zinc finger protein 143Nucleustranscription regulator
ZN333_HUMANZNF333zinc finger protein 333Nucleusother
ZN486_HUMANZNF486zinc finger protein 486Nucleusother
ZN516_HUMANZNF516zinc finger protein 516Nucleusother
ZN607_HUMANZNF607zinc finger protein 607Nucleusother
ZN645_HUMANZNF645zinc finger protein 645Extracellular Spaceother
ZN646_HUMANZNF646zinc finger protein 646Nucleusother
ZN770_HUMANZNF770zinc finger protein 770unknownother
ZN808_HUMANZNF808zinc finger protein 808unknownother
ZN865_HUMANZNF865zinc finger protein 865unknownother
ZNF98_HUMANZNF98zinc finger protein 98unknownother
Exo-pMSC-8%O2
ID Symbol Entrez Gene Name Location Type(s)
ACTS_HUMANACTA1actin, alpha 1, skeletal muscleCytoplasmother
ACTB_HUMANACTBactin, betaCytoplasmother
PACA_HUMANADCYAP1adenylate cyclase activating polypeptide 1 (pituitary)Extracellular Spaceother
FETA_HUMANAFPalpha-fetoproteinExtracellular Spacetransporter
FETUA_HUMANAHSGalpha-2-HS-glycoproteinExtracellular Spaceother
ALBU_HUMANALBalbuminExtracellular Spacetransporter
ANKH1_HUMANANKHD1ankyrin repeat and KH domain containing 1unknownother
ARMX1_HUMANARMCX1armadillo repeat containing, X-linked 1unknownother
ASXL3_HUMANASXL3additional sex combs like 3 (Drosophila)unknownother
ATG2B_HUMANATG2Bautophagy related 2Bunknownother
BAI1_HUMANBAI1brain-specific angiogenesis inhibitor 1Plasma MembraneG-protein coupled receptor
BCL3_HUMANBCL3B-cell CLL/lymphoma 3Nucleustranscription regulator
CL043_HUMANC12orf43chromosome 12 open reading frame 43unknownother
CO3_HUMANC3complement component 3Extracellular Spacepeptidase
CALB1_HUMANCALB1calbindin 1, 28 kDaCytoplasmother
CALR_HUMANCALRcalreticulinCytoplasmtranscription regulator
CAND1_HUMANCAND1cullin-associated and neddylation-dissociated 1Cytoplasmtranscription regulator
CAD20_HUMANCDH20cadherin 20, type 2Plasma Membraneother
CDK4_HUMANCDK4cyclin-dependent kinase 4Nucleuskinase
CEP97_HUMANCEP97centrosomal protein 97 kDaCytoplasmother
CIZ1_HUMANCIZ1CDKN1A interacting zinc finger protein 1Nucleustransporter
CMBL_HUMANCMBLcarboxymethylenebutenolidase homolog (Pseudomonas)unknownenzyme
CO1A1_HUMANCOL1A1collagen, type I, alpha 1Extracellular Spaceother
CO1A2_HUMANCOL1A2collagen, type I, alpha 2Extracellular Spaceother
CSF2R_HUMANCSF2RAcolony stimulating factor 2 receptor, alpha, low-affinity (granulocyte-macrophage)Plasma Membranetransmembrane receptor
CSTF3_HUMANCSTF3cleavage stimulation factor, 3′ pre-RNA, subunit 3, 77 kDaNucleusother
DIAC_HUMANCTBSchitobiase, di-N-acetyl-Cytoplasmenzyme
DG2L6_HUMANDGAT2L6diacylglycerol O-acyltransferase 2-like 6unknownother
DYH9_HUMANDNAH9dynein, axonemal, heavy chain 9Cytoplasmother
EMAL5_HUMANEML5echinoderm microtubule associated protein like 5unknownother
ENPP3_HUMANENPP3ectonucleotide pyrophosphatase/phosphodiesterase 3Plasma Membraneenzyme
FA10_HUMANF10coagulation factor XExtracellular Spacepeptidase
THRB_HUMANF2coagulation factor II (thrombin)Extracellular Spacepeptidase
FA73B_HUMANFAM73Bfamily with sequence similarity 73, member Bunknownother
FBN1_HUMANFBN1fibrillin 1Extracellular Spaceother
FLT3_HUMANFLT3fms-related tyrosine kinase 3Plasma Membranekinase
FINC_HUMANFN1fibronectin 1Extracellular Spaceenzyme
GLBL3_HUMANGLB1L3galactosidase, beta 1-like 3unknownenzyme
GP126_HUMANGPR126G protein-coupled receptor 126Plasma MembraneG-protein coupled receptor
GRIN1_HUMANGPRIN1G protein regulated inducer of neurite outgrowth 1Plasma Membraneother
HBD_HUMANHBDhemoglobin, deltaCytoplasmtransporter
HCFC2_HUMANHCFC2host cell factor C2Nucleustranscription regulator
IL25_HUMANIL25interleukin 25Extracellular Spacecytokine
INT4_HUMANINTS4integrator complex subunit 4Nucleusother
IQGA1_HUMANIQGAP1IQ motif containing GTPase activating protein 1Cytoplasmother
ITA4_HUMANITGA4integrin, alpha 4 (antigen CD49D, alpha 4 subunit of VLA-4 receptor)Plasma Membraneother
ITIH2_HUMANITIH2inter-alpha-trypsin inhibitor heavy chain 2Extracellular Spaceother
K0232_HUMANKIAA0232KIAA0232Extracellular Spaceother
SKT_HUMANKIAA1217KIAA1217Cytoplasmother
KNG1_HUMANKNG1kininogen 1Extracellular Spaceother
K2C1_HUMANKRT1keratin 1Cytoplasmother
K1C10_HUMANKRT10keratin 10Cytoplasmother
LMBL3_HUMANL3MBTL3l(3)mbt-like 3 (Drosophila)Nucleusother
LPHN2_HUMANLPHN2latrophilin 2Plasma MembraneG-protein coupled receptor
LRRC9_HUMANLRRC9leucine rich repeat containing 9unknownother
TRFL_HUMANLTFlactotransferrinExtracellular Spacepeptidase
MACF1_HUMANMACF1microtubule-actin crosslinking factor 1Cytoplasmenzyme
MCLN2_HUMANMCOLN2mucolipin 2Plasma Membraneion channel
M4A10_HUMANMS4A10membrane-spanning 4-domains, subfamily A, member 10unknownother
MYB_HUMANMYBv-myb myeloblastosis viral oncogene homolog (avian)Nucleustranscription regulator
ULA1_HUMANNAE1NEDD8 activating enzyme E1 subunit 1Cytoplasmenzyme
NFL_HUMANNEFLneurofilament, light polypeptideCytoplasmother
NOL4_HUMANNOL4nucleolar protein 4Nucleusother
NTF3_HUMANNTF3neurotrophin 3Extracellular Spacegrowth factor
O10A7_HUMANOR10A7olfactory receptor, family 10, subfamily A, member 7Plasma Membraneother
ORC1_HUMANORC1origin recognition complex, subunit 1Nucleusother
OSBL7_HUMANOSBPL7oxysterol binding protein-like 7Cytoplasmother
PARP8_HUMANPARP8poly (ADP-ribose) polymerase family, member 8unknownother
PCOC1_HUMANPCOLCEprocollagen C-endopeptidase enhancerExtracellular Spaceother
PENK_HUMANPENKproenkephalinExtracellular Spaceother
PHIP_HUMANPHIPpleckstrin homology domain interacting proteinNucleusother
PI3R4_HUMANPIK3R4phosphoinositide-3-kinase, regulatory subunit 4Cytoplasmkinase
PIWL1_HUMANPIWIL1piwi-like 1 (Drosophila)Cytoplasmother
PRDM9_HUMANPRDM9PR domain containing 9Nucleusenzyme
PYRD1_HUMANPYROXD1pyridine nucleotide-disulphide oxidoreductase domain 1unknownother
PZP_HUMANPZPpregnancy-zone proteinExtracellular Spaceother
RBL1_HUMANRBL1retinoblastoma-like 1 (p107)Nucleusother
THBG_HUMANSERPINA7serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 7Extracellular Spacetransporter
ANT3_HUMANSERPINC1serpin peptidase inhibitor, clade C (antithrombin), member 1Extracellular Spaceother
SHSA7_HUMANSHISA7shisa homolog 7 (Xenopus laevis)unknownother
S12A7_HUMANSLC12A7solute carrier family 12 (potassium/chloride transporters), member 7Plasma Membranetransporter
SMC4_HUMANSMC4structural maintenance of chromosomes 4Nucleustransporter
RU2B_HUMANSNRPB2small nuclear ribonucleoprotein polypeptide BNucleusother
OSTP_HUMANSPP1secreted phosphoprotein 1Extracellular Spacecytokine
SPP24_HUMANSPP2secreted phosphoprotein 2, 24 kDaExtracellular Spaceother
F10A1_HUMANST13suppression of tumorigenicity 13 (colon carcinoma) (Hsp70 interacting protein)Cytoplasmother
SPT6H_HUMANSUPT6Hsuppressor of Ty 6 homolog (S. cerevisiae)Nucleustranscription regulator
TRBP2_HUMANTARBP2TAR (HIV-1) RNA binding protein 2Nucleusother
TBL3_HUMANTBL3transducin (beta)-like 3Cytoplasmpeptidase
TET1_HUMANTET1tet methylcytosine dioxygenase 1Nucleusother
TRFE_HUMANTFtransferrinExtracellular Spacetransporter
TSP1_HUMANTHBS1thrombospondin 1Extracellular Spaceother
TM117_HUMANTMEM117transmembrane protein 117Cytoplasmother
TMTC3_HUMANTMTC3transmembrane and tetratricopeptide repeat containing 3unknownother
TPD53_HUMANTPD52L1tumor protein D52-like 1Cytoplasmother
TPM3_HUMANTPM3tropomyosin 3Cytoplasmother
TRAF3_HUMANTRAF3TNF receptor-associated factor 3Cytoplasmother
UB2V2_HUMANUBE2V2ubiquitin-conjugating enzyme E2 variant 2Cytoplasmenzyme
UHRF2_HUMANUHRF2ubiquitin-like with PHD and ring finger domains 2, E3 ubiquitin protein ligaseNucleusenzyme
UN13C_HUMANUNC13Cunc-13 homolog C (C. elegans)Cytoplasmother
VAMP5_HUMANVAMP5vesicle-associated membrane protein 5 (myobrevin)Plasma Membranetransporter
VAT1_HUMANVAT1vesicle amine transport protein 1 homolog (T. californica)Plasma Membranetransporter
MELT_HUMANVEPH1ventricular zone expressed PH domain homolog 1 (zebrafish)Nucleusother
VTNC_HUMANVTNvitronectinExtracellular Spaceother
1433B_HUMANYWHABtyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, beta polypeptideCytoplasmtranscription regulator
ZDH23_HUMANZDHHC23zinc finger, DHHC-type containing 23unknownother
ZMYM3_HUMANZMYM3zinc finger, MYM-type 3Nucleusother
ZN416_HUMANZNF416zinc finger protein 416Nucleusother
ZN671_HUMANZNF671zinc finger protein 671Nucleusother
ZNF74_HUMANZNF74zinc finger protein 74Nucleusother
ZN778_HUMANZNF778zinc finger protein 778unknownother
ZN841_HUMANZNF841zinc finger protein 841unknownother
Figure 6

Analysis of pMSC derived-exosomes proteins identified by mass spectrometry using PANTHER software.

Exosomal proteins isolated from pMSC exposed to 1%, 3% or 8% O2 were classified using PANTHER program based on their (A) Biological process and (B) Molecular function.

Figure 7

Ingenuity pathway analysis of pMSC derived-exosomes proteins.

(A) The Venn diagram depicts the distribution of common and unique proteins identified by nanospray LC-MS/MS (ABSciex 5600) in exosomes released from pMSC exposed to 1%, 3% and 8% oxygen. Comparison of canonical pathways: (B) actin cytoskeleton signaling, (C) growth hormone signaling, (D) VEGF signaling, and (E) clathrin-mediated endocytosis signaling identified by IPA core analysis. Values are mean ± SEM. In B, C, D and E, *p<0.005 versus all condition.

Analysis of pMSC derived-exosomes proteins identified by mass spectrometry using PANTHER software.

Exosomal proteins isolated from pMSC exposed to 1%, 3% or 8% O2 were classified using PANTHER program based on their (A) Biological process and (B) Molecular function.

Ingenuity pathway analysis of pMSC derived-exosomes proteins.

(A) The Venn diagram depicts the distribution of common and unique proteins identified by nanospray LC-MS/MS (ABSciex 5600) in exosomes released from pMSC exposed to 1%, 3% and 8% oxygen. Comparison of canonical pathways: (B) actin cytoskeleton signaling, (C) growth hormone signaling, (D) VEGF signaling, and (E) clathrin-mediated endocytosis signaling identified by IPA core analysis. Values are mean ± SEM. In B, C, D and E, *p<0.005 versus all condition.

Discussion

Mesenchymal stem cells are present in the human placenta during early pregnancy. During early pregnancy, placental vasculogenesis and angiogenesis proceed under low oxygen conditions prior to the establishment of a materno-placental perfusion. The role of MSC in directing and promoting placental vascular development remains to be clearly elucidated. The aim of this study was to establish the effects of oxygen tension on the release of exosomes from pMSC and to determine the effects of pMSC exosomes on endothelial cell migration and tube formation. The data obtained in the study are consistent with the hypothesis that the release of exosomes from pMSC is increased in hypoxic conditions and that pMSC exosomes promote endothelial cell migration and tube formation. Based on the data obtained, we suggest that pMSC exosomes contribute to the development of new vessels and promote angiogenesis within the placenta under low oxygen conditions. During early pregnancy this occurs as a physiological and developmental process. In pathological pregnancies characterized by compromized placental perfusion and ischaemia, such as preeclampsia and intrauterine growth restriction, we propose that pMSC may also increase exosome release as an adaptive response. Germane to any study seeking to elucidate the physiological or pathophysiological role of exosomes is their specific isolation. Several methods for isolating exosomes have been developed and partially characterized. These methods are primarily based on particle size and density. By definition, exosomes are nanovesicles with a diameter of 30–100 nm, a buoyant density of 1.12 to 1.19 g/ml and express characteristic cell-surface markers. In this study, pMSC exosomes were isolated by differential centrifuge and sucrose gradient purification and were characterized by a diameter of 50 nm, a buoyant density of 1.1270 g/ml, and expressed exosome-specific cell surface markers. Under hypoxic conditions (1% or 3% O2), pMSC exosome release increased by up to 7-fold compared to cells incubated under normoxic conditions (8% O2). These data are consistent with the effects of hypoxia on the release of exosomes from umbilical cord (UC)-derived MSCs, where low oxygen tension increases exosome release by ∼ 5.6-fold [37]. Hypoxia also has been reported to increase the release of exosomes from breast cancer cell lines (MCF7, SKBR3, and MDA- MB 231), squamous carcinoma cells (A431 cells) [26] and cardiac myocytes [38]. The mechanism by which hypoxia induces exosome release remains to be clearly established. Recent evidence suggests that increased release of exosomes from breast cancer cells under hypoxic condition may be mediated by transcriptional factor HIF-1α[39]. In this study, the authors also observed higher expression of miR-210 in exosomes isolated from cancer cells exposed to hypoxia compared to normaxia cell-derived exosomes. Exosomal miR-210 from metastatic cancer cells enhances endothelial cell angiogenesis [40]. In MSCs, HIFs have been reported to promote MSC-mediated angiogenic effect on endothelial cells through the release of interleukin 8, VEGF and other growth factors [41]. It has been demonstrated that the secretion of soluble VEGF requires functional ADP-ribosylation factor 6 (Arf6) [42]. Interestingly, Arf6 is expressed on the membrane of exosomes and may promote exosome release [43]. An association between VEGF and Arf6 within exosomes, however, has not yet been demonstrated. Similarly, HIFs may contribute to the hypoxia-induced release of exosomes from pMSC observed in this study. Previous studies have established that MSC promote angiogenesis via paracrine mechanisms [44]. The possible contribution of exosomes in mediating such paracrine actions has not been established. It is likely that exosomes were present (and not accounted for) in all conditioned media previously used to establish such paracrine effects. In this study, exosomes were isolated from pMSC, promoting hPMEC cell migration and tube formation. This effect was enhanced when pMSC were cultured under hypoxic conditions. Previously, Zhang et al., 2012, demonstrated that exosomes released from UC-MSC are internalized into umbilical cord endothelial cells and enhance in vitro the proliferation and network formation in a dose-dependent manner [37]. Interestingly, pMSC have ∼3.2-fold higher than that UC-MSC migration capacity [20]. Recently, Mineo et al., reported that the effect of exosomes on angiogenesis involves the Src family of kinases [45]. In addition, the role of Src family members in angiogenesis, promotion of tube formation and prevention of their regression has been reported [46], [47]. Recent commentary, suggests that mesenchymal stem cells-derived exosomes may not only afford therapeutic opportunities in regenerative medicine to repair damaged tissue but also in the cell-specific delivery of anticancer agents [48]. The exosomal content is highly dependent on the cell type and pre-conditioning. One of the first exosomal proteomes characterized was from mesothelioma cells, in which 38 different proteins were identified [49]. Studies in cancer cells show the great variability of proteins expressed in exosomes [50]–[54]. Supporting our results, exosomes isolated from a human first trimester cell line (Sw71) Atay et al., using an ion trap mass spectrometry approach, identified proteins implicated in a wide range of cellular processes including: cytoskeleton structure, ion channels, lysosomal degradation, molecular chaperones, amino-acid metabolism, carbohydrate metabolism, lipid metabolism, regulatory proteins, mRNA splicing, immune function and others [55]. Our study provides the first extensive analysis of the proteome of the exosomes derived-MSC primary culture, highlighting the extent of putative functional interactions that may be mediated by exosomes. Endothelial cell migration requires the initiation of numerous signaling pathways that remodels cytoskeleton. Also, actin and related proteins of cytoskeletal organization are critical for cell motility and migration. From the canonical pathway analysis, we found significantly more proteins associated with actin cytoskeleton, growth hormone, and VEGF signaling in exosomes isolated from pMSC exposed to 1% O2 compare to 3% or 8% O2. Likewise, clathrin-mediated endocytosis signaling was enhanced, possibly increasing the exosome uptake of target cells., Cell migration, however, is the final functional outcome of multiple pathways and the involvement of other regulatory moieties (e.g. miRNA) cannot be negated. In summary, pMSC isolated from first trimester placenta release exosomes in response to decreased oxygen tension. pMSC exosomes stimulate microvascular endothelial cells migration in a concentration and oxygen-dependent manner, and promote vascular network formation. The data obtained in this study are consistent with the hypothesis that under normal developmental conditions, pMSC promote vasculogenesis and angiogenesis within the early pregnancy placenta via a mechanism(s) involving exosomal trafficking to endothelial cells. We further suggest that in pathological pregnancies associated with under perfusion of the placenta, such as those complicated by pre-eclampsia and intra-uterine growth restriction, increased release of exosomes from pMSC may occur as an adaptive response.
  55 in total

1.  Isolation and characterization of exosomes from cell culture supernatants and biological fluids.

Authors:  Clotilde Théry; Sebastian Amigorena; Graça Raposo; Aled Clayton
Journal:  Curr Protoc Cell Biol       Date:  2006-04

2.  Carboxyamidotriazole-orotate inhibits the growth of imatinib-resistant chronic myeloid leukaemia cells and modulates exosomes-stimulated angiogenesis.

Authors:  Chiara Corrado; Anna Maria Flugy; Simona Taverna; Stefania Raimondo; Giuliana Guggino; Rashida Karmali; Giacomo De Leo; Riccardo Alessandro
Journal:  PLoS One       Date:  2012-08-03       Impact factor: 3.240

3.  Exosome secreted by MSC reduces myocardial ischemia/reperfusion injury.

Authors:  Ruenn Chai Lai; Fatih Arslan; May May Lee; Newman Siu Kwan Sze; Andre Choo; Tian Sheng Chen; Manuel Salto-Tellez; Leo Timmers; Chuen Neng Lee; Reida Menshawe El Oakley; Gerard Pasterkamp; Dominique P V de Kleijn; Sai Kiang Lim
Journal:  Stem Cell Res       Date:  2010-01-04       Impact factor: 2.020

4.  The endogenous retroviral envelope protein syncytin-1 inhibits LPS/PHA-stimulated cytokine responses in human blood and is sorted into placental exosomes.

Authors:  J M Tolosa; J E Schjenken; V L Clifton; A Vargas; B Barbeau; P Lowry; K Maiti; R Smith
Journal:  Placenta       Date:  2012-09-20       Impact factor: 3.481

5.  Internalization of exogenous ADP-ribosylation factor 6 (Arf6) proteins into cells.

Authors:  Syeda H Afroze; M Nasir Uddin; Xiaobo Cao; Alexzander Asea; Dawit Gizachew
Journal:  Mol Cell Biochem       Date:  2011-04-27       Impact factor: 3.396

6.  Physiological implications of the materno-fetal oxygen gradient in human early pregnancy.

Authors:  Eric Jauniaux; Beatrice Gulbis; Graham J Burton
Journal:  Reprod Biomed Online       Date:  2003-09       Impact factor: 3.828

7.  The inhibition of tube formation in a collagen-fibrinogen, three-dimensional gel by cleaved kininogen (HKa) and HK domain 5 (D5) is dependent on Src family kinases.

Authors:  Yuchuan Liu; Irma M Sainz; Yi Wu; Robin Pixley; Ricardo G Espinola; Sarmina Hassan; Mohammad M Khan; Robert W Colman
Journal:  Exp Cell Res       Date:  2007-10-18       Impact factor: 3.905

Review 8.  Therapeutic potential of mesenchymal stem cell-derived microvesicles.

Authors:  Luigi Biancone; Stefania Bruno; Maria Chiara Deregibus; Ciro Tetta; Giovanni Camussi
Journal:  Nephrol Dial Transplant       Date:  2012-08       Impact factor: 5.992

9.  Hypoxic enhancement of exosome release by breast cancer cells.

Authors:  Hamish W King; Michael Z Michael; Jonathan M Gleadle
Journal:  BMC Cancer       Date:  2012-09-24       Impact factor: 4.430

10.  Cardiomyocyte progenitor cell-derived exosomes stimulate migration of endothelial cells.

Authors:  K R Vrijsen; J P G Sluijter; M W L Schuchardt; B W M van Balkom; W A Noort; S A J Chamuleau; P A F M Doevendans
Journal:  J Cell Mol Med       Date:  2010-05-07       Impact factor: 5.310

View more
  132 in total

1.  Extracellular vesicles derived from human bone marrow mesenchymal stem cells promote angiogenesis in a rat myocardial infarction model.

Authors:  Suyan Bian; Liping Zhang; Liufa Duan; Xi Wang; Ying Min; Hepeng Yu
Journal:  J Mol Med (Berl)       Date:  2013-12-14       Impact factor: 4.599

2.  Mesenchymal Stromal Cell-Derived Extracellular Vesicles Protect the Fetal Brain After Hypoxia-Ischemia.

Authors:  Daan R M G Ophelders; Tim G A M Wolfs; Reint K Jellema; Alex Zwanenburg; Peter Andriessen; Tammo Delhaas; Anna-Kristin Ludwig; Stefan Radtke; Vera Peters; Leon Janssen; Bernd Giebel; Boris W Kramer
Journal:  Stem Cells Transl Med       Date:  2016-05-09       Impact factor: 6.940

3.  Tissue inhibitor of metalloproteinases-1 induces a pro-tumourigenic increase of miR-210 in lung adenocarcinoma cells and their exosomes.

Authors:  H Cui; B Seubert; E Stahl; H Dietz; U Reuning; L Moreno-Leon; M Ilie; P Hofman; H Nagase; B Mari; A Krüger
Journal:  Oncogene       Date:  2014-09-29       Impact factor: 9.867

4.  Biological properties of extracellular vesicles and their physiological functions.

Authors:  María Yáñez-Mó; Pia R-M Siljander; Zoraida Andreu; Apolonija Bedina Zavec; Francesc E Borràs; Edit I Buzas; Krisztina Buzas; Enriqueta Casal; Francesco Cappello; Joana Carvalho; Eva Colás; Anabela Cordeiro-da Silva; Stefano Fais; Juan M Falcon-Perez; Irene M Ghobrial; Bernd Giebel; Mario Gimona; Michael Graner; Ihsan Gursel; Mayda Gursel; Niels H H Heegaard; An Hendrix; Peter Kierulf; Katsutoshi Kokubun; Maja Kosanovic; Veronika Kralj-Iglic; Eva-Maria Krämer-Albers; Saara Laitinen; Cecilia Lässer; Thomas Lener; Erzsébet Ligeti; Aija Linē; Georg Lipps; Alicia Llorente; Jan Lötvall; Mateja Manček-Keber; Antonio Marcilla; Maria Mittelbrunn; Irina Nazarenko; Esther N M Nolte-'t Hoen; Tuula A Nyman; Lorraine O'Driscoll; Mireia Olivan; Carla Oliveira; Éva Pállinger; Hernando A Del Portillo; Jaume Reventós; Marina Rigau; Eva Rohde; Marei Sammar; Francisco Sánchez-Madrid; N Santarém; Katharina Schallmoser; Marie Stampe Ostenfeld; Willem Stoorvogel; Roman Stukelj; Susanne G Van der Grein; M Helena Vasconcelos; Marca H M Wauben; Olivier De Wever
Journal:  J Extracell Vesicles       Date:  2015-05-14

Review 5.  Mesenchymal Stem Cell-derived Extracellular Vesicles: Toward Cell-free Therapeutic Applications.

Authors:  Sweta Rani; Aideen E Ryan; Matthew D Griffin; Thomas Ritter
Journal:  Mol Ther       Date:  2015-03-19       Impact factor: 11.454

Review 6.  Exosome and its roles in cardiovascular diseases.

Authors:  Wang Zhao; Xi-Long Zheng; Shui-Ping Zhao
Journal:  Heart Fail Rev       Date:  2015-05       Impact factor: 4.214

Review 7.  Placental extracellular vesicles and feto-maternal communication.

Authors:  M Tong; L W Chamley
Journal:  Cold Spring Harb Perspect Med       Date:  2015-01-29       Impact factor: 6.915

Review 8.  Mesenchymal Stem Cell (MSC)-Derived Extracellular Vesicles: Potential Therapeutics as MSC Trophic Mediators in Regenerative Medicine.

Authors:  Qi-Ling Yuan; Yin-Gang Zhang; Qian Chen
Journal:  Anat Rec (Hoboken)       Date:  2019-06-17       Impact factor: 2.064

Review 9.  Exosomal therapy-a new frontier in regenerative medicine.

Authors:  Sathish Muthu; Asawari Bapat; Rashmi Jain; Naveen Jeyaraman; Madhan Jeyaraman
Journal:  Stem Cell Investig       Date:  2021-04-02

10.  Biomaterials functionalized with MSC secreted extracellular vesicles and soluble factors for tissue regeneration.

Authors:  Meadhbh Á Brennan; Pierre Layrolle; David J Mooney
Journal:  Adv Funct Mater       Date:  2020-03-11       Impact factor: 18.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.